Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. On July 28th, the Food and Drug Administration (FDA) approved the ...

Semglee (insulin glargine) may be substituted for the reference product, Lantus, at the pharmacy counter and without the intervention of the prescriber. The Food and Drug Administration (FDA) has ...

Semglee™ (insulin glargine injection; Mylan and Biocon Biologics) is now available to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.

Mylan and Biocon’s NDA for Semglee (insulin glargine injection), was approved last week by the FDA, making it the third product approved by the FDA through the Mylan-Biocon Biologics collaboration.

Express Scripts will prefer the first Food and Drug Administration-approved interchangeable biosimilar product, a move it says will lead to millions in savings. Semglee, which was developed by Viatris ...

Pharmaceutical companies Biocon Biologics and Mylan announced at the end of last month the U.S. launch of their long-acting insulin glargine product Semglee. Semglee was approved in June as an ...

(RTTNews) - Viatris Inc. (VTRS) and Biocon Biologics said that they received an approval from the U.S. Food and Drug Administration for the first Interchangeable Biosimilar Semglee (insulin ...

(RTTNews) - Mylan N.V. (MYL) and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., on Monday, announced the U.S. launch of Semglee in vial and pre-filled pen presentations, approved to help ...

One batch of Semglee prefilled insulin injection pens has been recalled by Mylan Pharmaceuticals for missing labels. Batch No. BF20003118, expiration August 2022 of Semglee (insulin glargine injection ...

Semglee™ (insulin glargine injection; Mylan and Biocon Biologics) is now available to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.